Q-omics provides the consensus-scored NDUFA9 profile across patient tissues and cancer cell-line models. NDUFA9 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NDUFA9 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, NDUFA9 protein abundance shows 29,829 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, BLCA, and GBM as cancer lineages where NDUFA9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFA9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFA9 survival associations across molecular data types. NDUFA9 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFA9 RNA expression–survival associations across cancer types. High NDUFA9 expression shows unfavorable associations in UVM, UCS, LUAD and ACC, but favorable associations in KIRP and READ. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NDUFA9 RNA expression.
This table summarizes NDUFA9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 8. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFA9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFA9 shows higher tumor expression in BLCA, LIHC, BRCA, STAD, LUSC and UCEC. The BLCA box plot shows higher NDUFA9 RNA expression in tumor versus normal tissue (log2 FC = +0.543, t-test p < 0.001).
This table shows molecular features associated with NDUFA9 in patient tissues and cancer cell lines. In patient samples, NDUFA9 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFA9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and UPPER_AERODIGESTIVE_TRACT.
